Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Treatment"

Mopic / shutterstock.com

Research Targets Interferon Alpha in New Treatment Approach for CNS Lupus

Mary Beth Nierengarten  |  November 9, 2017

RETRACTED Editor’s note: The study this article reported on was retracted by the researchers. Key aspects could not be replicated, and they said, “Most importantly, the findings from behaviour studies and sequencing of microglia isolated from 564Igi autoimmune mice as shown in Figs. 1a, b, d and 3a, b are not substantiated upon further analysis…

Systemic Sclerosis Mortality Rate May Be Underestimated

Kurt Ullman  |  November 6, 2017

Systemic sclerosis (SSc) is a disease characterized by immunologic abnormalities, microvascular involvement and tissue fibrosis. In previous studies, 10-year survival rates ranged from 50–84%. However, there are concerns that these studies, using prevalent cohorts, are underestimating mortality. “While the prognosis of many rheumatic diseases has improved with the availability of more effective and targeted therapies,…

Can Osteoarthritis Be Reversed?

Elizabeth Hofheinz, MPH, MEd  |  November 6, 2017

You may say the 30 million Americans with osteoarthritis (OA) are walking around with a Band-aid—or so it seems.1 That’s because there’s no actual cure for this disabling condition. However, an inter­national group of scientists is making headway on a method of eliminating aging—senescent—cells as a way to prevent or even reverse OA. Cartilage Disappears,…

Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus

Thomas R. Collins  |  October 17, 2017

MADRID—Researchers have found that systemic lupus erythematosus (SLE) is independently linked with bipolar disorder and say the findings point to a need for greater awareness of psychiatric problems in patients with SLE. In work led by investigators at Tel Aviv University in Israel and presented at the 2017 Annual European Congress on Rheumatology (EULAR), researchers…

Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

Lara C. Pullen, PhD  |  October 17, 2017

CHICAGO—Joseph Breen, PhD, program officer at the National Institutes of Health in Bethesda, Md., opened the chronic fatigue syndrome (CFS) session at the Federation of Clinical Immunology Societies (FOCIS) 2017 meeting by asking presenters to describe the current state of the science to the key immunology stakeholders gathered in the room. The hope was that…

Accelerating Medicines Partnership Shares Its Progress on RA/Lupus Network

Lara C. Pullen, PhD  |  October 17, 2017

CHICAGO—“Why do so many drugs fail in clinical trials?” asked Michael Brenner, MD, chief of rheumatology, immunology and allergy at Brigham and Women’s Hospital in Boston. This question, previously posed by Francis Collins, MD, PhD, director of the National Institutes of Health, prompted a discussion among scientists and stakeholders in the pharmaceutical industry. The conversation…

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

Vanessa Caceres  |  October 17, 2017

As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

How Juvenile Idiopathic Arthritis Affects Patients, Families

Catherine I. Morlino  |  October 17, 2017

After having had juvenile idiopathic arthritis (JIA) for 20 years, I had a moment in my journey when I realized something new: “Your arthritis doesn’t just affect you, you know,” my sister said. This statement stopped me in my achy tracks. For two decades, I had been operating under the assumption that JIA was my…

Oksana Shufrych TKTK / Shutterstock.com

Heated Gloves May Improve Hand Function in Diffuse Systemic Sclerosis

Rosemarie Curley, MPT, DPT, & Jeananne Elkins, PT, PhD, DPT, MPH  |  October 16, 2017

Systemic sclerosis (SSc), a subtype of scleroderma, is a rare, complex autoimmune disease characterized by widespread vasculopathy of the small arteries and fibroblast dysfunction.1,2 It has been described as a fibrosing micro­vascular disease, because vascular injury precedes and leads to tissue fibrosis.3 The resulting Raynaud’s phenomenon, pain, skin thickening and tightening, and multi-organ involvement have…

TNF Inhibitor Drug Tapering Successful in Some Patients with RA

Thomas R. Collins  |  September 19, 2017

MADRID—Scores on the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) and C-reactive protein (CRP) levels were independent predictors of whether patients could be tapered successfully from a TNF inhibitor after having reached remission of their RA, according to findings presented in a session at the Annual European Congress of Rheumatology. Researchers also developed a composite…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences